<DOC>
	<DOC>NCT00312572</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of dose conversion from hydrocodone/ acetaminophen (Vicodin®) to the buprenorphine transdermal system (Butrans™) in subjects with osteoarthritis pain of the hip or knee. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication will be allowed.</brief_summary>
	<brief_title>Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain</brief_title>
	<detailed_description>Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>osteoarthritis of the hip or knee taking a regularly scheduled regimen of hydrocodone/ acetaminophen for their osteoarthritis OA pain. currently have condition requiring a stable regimen of acetaminophen (APAP). a history of chronic conditions, other than OA of the hip or knee joints, requiring frequent, intermittent analgesic therapy. Other protocolspecific exclusion/inclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Osteoarthritis, opioid, transdermal</keyword>
</DOC>